Introducing candesartan 32 mg plus hydrochlorothiazide 25 mg in previously untreated patients with severe essential hypertension

Por Baumgart, Peter, Naudts, Ingomar, Kiel, Gerhard
Publicado no Pragmat Obs Res (2011)

EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry

Por Gitt, Anselm K, Baumgart, Peter, Bramlage, Peter, Mahfoud, Felix, Potthoff, Sebastian A, Senges, Jochen, Schneider, Steffen, Buhck, Hartmut, Schmieder, Roland E
Publicado em 2013

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights...

Por Bramlage, Peter, Schmieder, Roland E., Gitt, Anselm K., Baumgart, Peter, Mahfoud, Felix, Buhck, Hartmut, Ouarrak, Taoufik, Ehmen, Martina, Potthoff, Sebastian A.
Publicado no Trials (2015)

Functional and Structural Profiling of the Human Thrombopoietin Gene Promoter

Por Dördelmann, Corinna, Telgmann, Ralph, Brand, Eva, Hagedorn, Claudia, Schröer, Bianca, Hasenkamp, Sandra, Baumgart, Peter, Kleine-Katthöfer, Peter, Paul, Martin, Brand-Herrmann, Stefan-Martin
Publicado em 2008

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry

Por Gitt, Anselm K., Bramlage, Peter, Potthoff, Sebastian A., Baumgart, Peter, Mahfoud, Felix, Buhck, Hartmut, Ehmen, Martina, Ouarrak, Taoufik, Senges, Jochen, Schmieder, Roland E.
Publicado no BMC Cardiovasc Disord (2016)